Latest News & Features
Big Pharma
The UK Competition and Markets Authority has welcomed a Court of Appeal ruling allowing it to press ahead with cases against Pfizer and Flynn Pharma over the unfair pricing of an epilepsy treatment. 12 March 2020
Americas
The University of Texas has asked the Supreme Court to rule that state-owned institutions should escape the normal rules determining the appropriate venue for filing patent lawsuits. 12 March 2020
Big Pharma
The European Medicines Agency has said that no drug shortages or supply disruptions due to the coronavirus outbreak have been reported, but that a steering group has convened to address the epidemic’s impact on the supply of medicines in the EU. 11 March 2020
Americas
US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices. 10 March 2020
Big Pharma
The AARP has urged the US Court of Appeals for the Ninth Circuit to uphold a newly-formed California law prohibiting the majority of pay-for-delay pharmaceutical settlements. 10 March 2020
Americas
A Virginia judge has approved Par Pharmaceutical’s settlement with a group of direct purchasers, allowing the pharmaceutical company to escape a pay-for-delay lawsuit. 10 March 2020
Big Pharma
EU authorities seized €7.9 million worth of counterfeit medicines—including fake cancer drugs, antivirals, and erectile dysfunction medicines—as part of an operation carried out last year. 9 March 2020
Big Pharma
The search for clarity goes on as Broad gears up for another set of legal challenges, as Claire Irvine, partner at HGF, explains. 6 March 2020
Americas
Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company. 5 March 2020
Big Pharma
Cooley has grown its IP litigation practice with the addition of partners Sanya Sukduang and Jonathan Davies, who will be based in Washington, DC. 5 March 2020